{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:06:28Z","timestamp":1793387188332,"version":"4.5.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gut Pathog"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) remains a lethal complication of chronic hepatitis C virus (HCV) infection, even after successful direct-acting antiviral (DAA) therapy. The gut microbiome influences hepatocarcinogenesis through the gut\u2012liver axis; however, the microbial signatures associated with HCC in DAA-treated patients are poorly defined. This study aimed to elucidate the patterns of microbiomes in HCV-treated patients who developed HCC, with a focus on bacterial diversity, differentially represented taxa, and their associations with clinical markers (FIB-4) and metabolic profiles as potential biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 138 participants were enrolled: 46 HCC patients with persistent HCV viremia (RHCC), 46 HCC patients with HCV eradication (THCC), and 46 healthy controls. RHCC patients exhibited pronounced dysbiosis, characterized by reduced alpha diversity (Kruskal\u2013Wallis; H\u2009=\u200914.37,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00076) and an elevated Firmicutes\/Bacteroidetes (F\/B) ratio (1.55 vs. 1.05 in controls; Mann\u2013Whitney U test, U\u2009=\u200987.32,\n                      <jats:italic>padj<\/jats:italic>\n                      \u2009=\u20090.00079). At the genus level,\n                      <jats:italic>Asteroleplasma<\/jats:italic>\n                      was significantly enriched in RHCC (log\u2082FC\u2009= +\u20092.8,\n                      <jats:italic>padj<\/jats:italic>\n                      \u2009=\u20090.008), whereas the butyrate-producing genus\n                      <jats:italic>Faecalibacterium<\/jats:italic>\n                      was depleted (log\u2082FC\u2009= \u2212\u20092.1,\n                      <jats:italic>padj<\/jats:italic>\n                      \u2009=\u20090.006). Machine learning identified\n                      <jats:italic>Asteroleplasma, Moryella, Lachnoclostridium, Fournierella, Eubacterium xylanophilum, Succinivibrio<\/jats:italic>\n                      , and\n                      <jats:italic>Faecalibacterium<\/jats:italic>\n                      as the top classifiers of RHCC (AUC\u2009=\u20090.81). Functional profiling revealed a 58% reduction in butyrate synthesis (\n                      <jats:italic>padj<\/jats:italic>\n                      \u2009=\u20090.0032) and increased lipopolysaccharide biosynthesis (log\u2082FC\u2009= +\u20093.2,\n                      <jats:italic>padj<\/jats:italic>\n                      \u2009=\u20090.002) in RHCC, both of which correlated with clinical deterioration (FIB-4 scores,\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.62).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Distinct gut microbial signatures distinguish HCC patients with persistent HCV viremia from those who achieve viral clearance, with implications for risk stratification and therapeutic targeting. The F\/B ratio,\u00a0abundance of\n                      <jats:italic>Asteroleplasma<\/jats:italic>\n                      , and functional pathway disruption (butyrate depletion) could serve as potential biomarkers for HCC progression. These findings underscore the influential role of the gut microbiome in hepatocarcinogenesis and its potential utility in personalized HCC management.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13099-025-00761-w","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:47:52Z","timestamp":1763142472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Gut microbiome dysbiosis in hepatocellular carcinoma patients with persistent HCV viremia versus viral clearance: a cross-sectional study"],"prefix":"10.1186","volume":"17","author":[{"given":"Hany R.","family":"Hashem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasnem","family":"Yehia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Abdellah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim A.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Salah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4577-0418","authenticated-orcid":false,"given":"Mohammed","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"1","key":"761_CR1","first-page":"99","volume":"5","author":"N Osama","year":"2025","unstructured":"Osama N, Amer NN, Mohamed AA, Salah M, Ezz Al Arab MR, El-Awady RR. Comparison between miR-199b-5p and AFP in the diagnosis of hepatitis C-associated hepatocellular carcinoma. Azhar International J Pharmaceutical Med Sci. 2025;5(1):99\u2013108.","journal-title":"Azhar International J Pharmaceutical Med Sci"},{"issue":"2","key":"761_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.102446","volume":"15","author":"SP Singh","year":"2025","unstructured":"Singh SP, Madke T, Chand P. Global epidemiology of hepatocellular carcinoma. J Clin Exp Hepatol. 2025;15(2):102446.","journal-title":"J Clin Exp Hepatol"},{"issue":"5","key":"761_CR3","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/ans.15647","volume":"90","author":"MA Salman","year":"2020","unstructured":"Salman MA, Omar HS, Mikhail HM, Tourky M, El\u2010ghobary M, Elkassar H, et al. Sarcopenia increases 1\u2010year mortality after surgical resection of hepatocellular carcinoma. ANZ J Surg. 2020;90(5):781\u20135.","journal-title":"ANZ J Surg"},{"issue":"3","key":"761_CR4","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"761_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"761_CR6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","volume":"7","author":"S Blach","year":"2022","unstructured":"Blach S, Terrault NA, Tacke F, Gamkrelidze I, Craxi A, Tanaka J, et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396\u2013415.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"761_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","volume":"72","author":"GN Ioannou","year":"2020","unstructured":"Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2020;72(1):25\u201336.","journal-title":"J Hepatol"},{"issue":"1","key":"761_CR8","first-page":"17","volume":"5","author":"N Fekry","year":"2025","unstructured":"Fekry N, Abd Elmaqsoud ELS, Al Kasaby Z, Abu-ElFotuh K. Hepatocellular carcinoma after treatment of cirrhotic Hepatitis C Virus patients with direct acting antiviral treatment. Azhar International J Pharmaceutical Med Sci. 2025;5(1):17\u201326.","journal-title":"Azhar International J Pharmaceutical Med Sci"},{"issue":"3","key":"761_CR9","first-page":"666","volume":"163","author":"HB El-Serag","year":"2022","unstructured":"El-Serag HB, Kanwal F, Feng Z. Risk factors for cirrhosis in contemporary hepatology practices - findings from the Texas Hepatocellular Carcinoma Consortium cohort. Gastroenterology. 2022;163(3):666\u201378.","journal-title":"Gastroenterology"},{"key":"761_CR10","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00118.2019","author":"SAM Albhaisi","year":"2020","unstructured":"Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2020. https:\/\/doi.org\/10.1152\/ajpgi.00118.2019.","journal-title":"American Journal of Physiology-Gastrointestinal and Liver Physiology"},{"issue":"6","key":"761_CR11","first-page":"397","volume":"18","author":"A Tripathi","year":"2021","unstructured":"Tripathi A, Debelius J, Brenner DA. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2021;18(6):397\u2013411.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"761_CR12","first-page":"e00224","volume":"8","author":"S Csader","year":"2023","unstructured":"Csader S, Chen X, Leung H, M\u00e4nnist\u00f6 V, Pentik\u00e4inen H, Tauriainen M-M, et al. Schwab U. Panagiotou G: Gut ecol net reveal associations between bacteria, exercise, clinical profile in non-alcoholic fatty liver disease patients. 2023;8(5):e00224-e1223.","journal-title":"Panagiotou G: Gut ecol net reveal associations between bacteria, exercise, clinical profile in non-alcoholic fatty liver disease patients"},{"issue":"1","key":"761_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-025-00698-0","volume":"17","author":"H Sammallahti","year":"2025","unstructured":"Sammallahti H, Rezasoltani S, Pekkala S, Kokkola A, Asadzadeh Agdaei H, Azizmohammad Looha M, et al. Fecal profiling reveals a common microbial signature for pancreatic cancer in Finnish and Iranian cohorts. Gut Pathog. 2025;17(1):24.","journal-title":"Gut Pathog"},{"key":"761_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13099-016-0124-2","volume":"8","author":"AM Aly","year":"2016","unstructured":"Aly AM, Adel A, El-Gendy AO, Essam TM, Aziz RK. Gut microbiome alterations in patients with stage 4 hepatitis C. Gut pathogens. 2016;8:1\u201312.","journal-title":"Gut pathogens"},{"issue":"1","key":"761_CR15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/acer.13911","volume":"43","author":"JS Bajaj","year":"2019","unstructured":"Bajaj JS, Kakiyama G, Zhao D, Fagan A, Daita K, Gavis EA, et al. Continued alcohol misuse in human cirrhosis is associated with an impaired gut-liver axis. Alcohol Clin Exp Res. 2019;43(1):123\u201332.","journal-title":"Alcohol Clin Exp Res"},{"issue":"10","key":"761_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","volume":"20","author":"L Hammerich","year":"2023","unstructured":"Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis. Nat Rev Gastroenterol Hepatol. 2023;20(10):633\u201346.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"761_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hep.30036","volume":"69","author":"FR Ponziani","year":"2019","unstructured":"Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L, Del Chierico F, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology. 2019;69(1):107\u201320.","journal-title":"Hepatology"},{"issue":"9","key":"761_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092099","volume":"14","author":"S Shen","year":"2022","unstructured":"Shen S, Khatiwada S, Behary J, Kim R, Zekry A. Modulation of the gut microbiome to improve clinical outcomes in hepatocellular carcinoma. Cancers (Basel). 2022;14(9):2099.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"761_CR19","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1053\/j.gastro.2021.04.074","volume":"161","author":"F Kanwal","year":"2021","unstructured":"Kanwal F, Kramer J, Asch SM. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2021;161(3):995\u20131005.","journal-title":"Gastroenterology"},{"issue":"3","key":"761_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/msystems.00153-20","volume":"5","author":"Y Lapidot","year":"2020","unstructured":"Lapidot Y, Amir A, Nosenko R, Uzan-Yulzari A, Veitsman E, Cohen-Ezra O, et al. Alterations in the gut microbiome in the progression of cirrhosis to hepatocellular carcinoma. mSystems. 2020;5(3):10\u20131128.","journal-title":"mSystems"},{"issue":"12","key":"761_CR21","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.3390\/cancers13123025","volume":"13","author":"S Brozzetti","year":"2021","unstructured":"Brozzetti S, Tancredi M, Bini S, De Lucia C, Antimi J, D\u2019Alterio C, et al. Hcc in the era of direct-acting antiviral agents (DAAs): surgical and other curative or palliative strategies in the elderly. Cancers. 2021;13(12):3025.","journal-title":"Cancers"},{"issue":"8","key":"761_CR22","first-page":"1345","volume":"29","author":"M El-Mowafy","year":"2023","unstructured":"El-Mowafy M, El-Mesery M, El-Kadem AH. Changes in gut microbiome composition following direct-acting antiviral therapy in hepatitis C patients. World J Gastroenterol. 2023;29(8):1345\u201360.","journal-title":"World J Gastroenterol"},{"key":"761_CR23","doi-asserted-by":"crossref","unstructured":"Abosheaishaa H, Abdelmalek A, Omar A, Islam M, Samah M, Mohammed Y, Ahmed S, A. BA, Ahmed S, S. NM et al 2024: The Egyptian journey from having the highest prevalence of hepatitis C virus to being the first to achieve \u201cgold tier\u201d in conquering the disease. Baylor University Medical Center Proceedings, 37(5):877\u2013883.","DOI":"10.1080\/08998280.2024.2379185"},{"issue":"1","key":"761_CR24","first-page":"22","volume":"71","author":"C Caussy","year":"2020","unstructured":"Caussy C, Hsu C, Lo M-T, Liu A, Bettencourt R, Ajmera VH, et al. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology. 2020;71(1):22\u201335.","journal-title":"Hepatology"},{"issue":"15","key":"761_CR25","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1093\/bioinformatics\/btv183","volume":"31","author":"BJ Kelly","year":"2015","unstructured":"Kelly BJ, Gross R, Bittinger K, Sherrill-Mix S, Lewis JD, Collman RG, et al. Power and sample-size estimation for microbiome studies using pairwise distances and PERMANOVA. Bioinformatics. 2015;31(15):2461\u20138.","journal-title":"Bioinformatics"},{"issue":"1","key":"761_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"EASL","year":"2017","unstructured":"EASL. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153\u201394.","journal-title":"J Hepatol"},{"issue":"4","key":"761_CR27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s12072-018-9868-8","volume":"12","author":"A Abdel-Moneim","year":"2018","unstructured":"Abdel-Moneim A, Aboud A, Abdel-Gabaar M, Zanaty MI, Ramadan M. Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4. Hepatol Int. 2018;12(4):348\u201355.","journal-title":"Hepatol Int"},{"issue":"20","key":"761_CR28","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical A","year":"2013","unstructured":"World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"key":"761_CR29","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/jvh.12816","volume":"25","author":"W El-Akel","year":"2018","unstructured":"El-Akel W, El-Sayed MH, El Kassas M. National treatment program of hepatitis C in Egypt: hepatitis C virus model of care. J Viral Hepat. 2018;25:262\u20137.","journal-title":"J Viral Hepat"},{"issue":"2","key":"761_CR30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723\u201350.","journal-title":"Hepatology"},{"issue":"1","key":"761_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s43055-023-01083-0","volume":"54","author":"AH Abduljabbar","year":"2023","unstructured":"Abduljabbar AH, Wazzan MA. Diagnostic performance of US LI-RADS in hepatocellular carcinoma surveillance. Egypt J Radiol Nucl Med. 2023;54(1):134.","journal-title":"Egypt J Radiol Nucl Med"},{"key":"761_CR32","first-page":"12","volume":"8","author":"D Omran","year":"2022","unstructured":"Omran D, Alboraie M, Zayed RA. GALAD score for early detection of hepatocellular carcinoma in Egyptian patients with chronic HCV. Clin Exp Hepatol. 2022;8:12\u20138.","journal-title":"Clin Exp Hepatol"},{"issue":"5","key":"761_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1089\/omi.2019.0011","volume":"23","author":"M Ramadan","year":"2019","unstructured":"Ramadan M, Solyman S, Yones M, Abdallah Y, Halaby H, Hanora A. Skin microbiome differences in atopic dermatitis and healthy controls in Egyptian children and adults, and association with serum immunoglobulin E. OMICS. 2019;23(5):247\u201360.","journal-title":"OMICS"},{"issue":"7","key":"761_CR34","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","volume":"13","author":"BJ Callahan","year":"2016","unstructured":"Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581\u20133.","journal-title":"Nat Methods"},{"issue":"D1","key":"761_CR35","doi-asserted-by":"publisher","first-page":"D590","DOI":"10.1093\/nar\/gks1219","volume":"41","author":"C Quast","year":"2013","unstructured":"Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2013;41(D1):D590\u20136.","journal-title":"Nucleic Acids Res"},{"issue":"16","key":"761_CR36","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.1128\/AEM.00062-07","volume":"73","author":"Q Wang","year":"2007","unstructured":"Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007;73(16):5261\u20137.","journal-title":"Appl Environ Microbiol"},{"issue":"1","key":"761_CR37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57(1):289\u2013300.","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"761_CR38","doi-asserted-by":"crossref","unstructured":"Anderson MJ: Permutational Multivariate Analysis of Variance (PERMANOVA). Wiley StatsRef: Statistics Reference Online 2017:1\u201315.","DOI":"10.1002\/9781118445112.stat07841"},{"issue":"12","key":"761_CR39","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"11","key":"761_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1009442","volume":"17","author":"H Mallick","year":"2021","unstructured":"Mallick H, Rahnavard A, McIver LJ, Ma S, Zhang Y, Nguyen LH, et al. Multivariable association discovery in population-scale meta-omics studies. PLoS Comput Biol. 2021;17(11):e1009442.","journal-title":"PLoS Comput Biol"},{"issue":"7346","key":"761_CR41","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/nature09944","volume":"473","author":"M Arumugam","year":"2011","unstructured":"Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174\u201380.","journal-title":"Nature"},{"issue":"W1","key":"761_CR42","doi-asserted-by":"publisher","first-page":"W180","DOI":"10.1093\/nar\/gkx295","volume":"45","author":"A Dhariwal","year":"2017","unstructured":"Dhariwal A, Chong J, Habib S, King IL, Agellon LB, Xia J. MicrobiomeAnalyst: a web-based tool for comprehensive statistical, visual and meta-analysis of microbiome data. Nucleic Acids Res. 2017;45(W1):W180-w188.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"761_CR43","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/j.1574-6976.2010.00251.x","volume":"35","author":"D Knights","year":"2011","unstructured":"Knights D, Costello EK, Knight R. Supervised classification of human microbiota. FEMS Microbiol Rev. 2011;35(2):343\u201359.","journal-title":"FEMS Microbiol Rev"},{"issue":"17","key":"761_CR44","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1093\/bioinformatics\/btv287","volume":"31","author":"KP A\u00dfhauer","year":"2015","unstructured":"A\u00dfhauer KP, Wemheuer B, Daniel R, Meinicke P. Tax4fun: predicting functional profiles from metagenomic 16S rRNA data. Bioinformatics. 2015;31(17):2882\u20134.","journal-title":"Bioinformatics"},{"issue":"1","key":"761_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27\u201330.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"761_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004977","volume":"12","author":"E Pasolli","year":"2016","unstructured":"Pasolli E, Truong DT, Malik F, Waldron L, Segata N. Machine learning meta-analysis of large metagenomic datasets: tools and biological insights. PLoS Comput Biol. 2016;12(7):e1004977.","journal-title":"PLoS Comput Biol"},{"key":"761_CR47","doi-asserted-by":"crossref","unstructured":"Luo W, Guo S, Zhou Y, Zhao J, Wang M, Sang L, Chang B, Wang B: Hepatocellular Carcinoma: How the Gut Microbiota Contributes to Pathogenesis, Diagnosis, and Therapy. Frontiers in microbiology 2022, Volume 13 - 2022.","DOI":"10.3389\/fmicb.2022.873160"},{"key":"761_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8071011","author":"NM Elsherbiny","year":"2020","unstructured":"Elsherbiny NM, Rammadan M, Hassan EA, Ali ME, El-Rehim ASA, Abbas WA, et al. Autoimmune hepatitis: shifts in gut microbiota and metabolic pathways among Egyptian patients. Microorganisms. 2020. https:\/\/doi.org\/10.3390\/microorganisms8071011.","journal-title":"Microorganisms"},{"key":"761_CR49","first-page":"2","volume":"14","author":"E Monti","year":"2025","unstructured":"Monti E, Vianello C, Leoni I, Galvani G, Lippolis A, D\u2019Amico F, et al. Gut Microbiome Modulation Hepatocell Carcinoma: Preventive Role in NAFLD\/NASH Progression Potential Applications Immunotherapy-Based Strategies Cells. 2025;14:2.","journal-title":"Gut Microbiome Modulation Hepatocell Carcinoma: Preventive Role in NAFLD\/NASH Progression Potential Applications Immunotherapy-Based Strategies Cells"},{"issue":"19","key":"761_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194875","volume":"15","author":"B Gok Yavuz","year":"2023","unstructured":"Gok Yavuz B, Datar S, Chamseddine S, Mohamed YI, LaPelusa M, Lee SS, et al. The gut microbiome as a biomarker and therapeutic target in hepatocellular carcinoma. Cancers (Basel). 2023;15(19):4875.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"761_CR51","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/gutjnl-2017-315084","volume":"68","author":"Z Ren","year":"2019","unstructured":"Ren Z, Li A, Jiang J, Zhou L, Yu Z, Lu H, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;68(6):1014\u201323.","journal-title":"Gut"},{"issue":"10","key":"761_CR52","doi-asserted-by":"publisher","DOI":"10.1093\/jambio\/lxad221","volume":"134","author":"J Feng","year":"2023","unstructured":"Feng J, Wu Y, Dai P, Wang D, Liu L, Chai B. Gut microbial signatures of patients with primary hepatocellular carcinoma and their healthy first-degree relatives. J Appl Microbiol. 2023;134(10):lxad221.","journal-title":"J Appl Microbiol"},{"issue":"11","key":"761_CR53","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","volume":"34","author":"H Tilg","year":"2022","unstructured":"Tilg H, Adolph TE, Trauner M. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab. 2022;34(11):1700\u201318.","journal-title":"Cell Metab"},{"issue":"3","key":"761_CR54","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020;72(3):558\u201377.","journal-title":"J Hepatol"},{"key":"761_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2023-100020","author":"Y Wen","year":"2023","unstructured":"Wen Y, Ma L, Ju C. Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases. Egastroenterology. 2023. https:\/\/doi.org\/10.1136\/egastro-2023-100020.","journal-title":"Egastroenterology"},{"issue":"8","key":"761_CR56","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/infdis\/jiab094","volume":"224","author":"N Chuaypen","year":"2021","unstructured":"Chuaypen N, Jinato T, Avihingsanon A, Chirapongsathorn S, Cheevadhanarak S, Nookaew I, et al. Improvement of gut diversity and composition after direct-acting antivirals in hepatitis C virus-infected patients with or without human immunodeficiency virus coinfection. J Infect Dis. 2021;224(8):1410\u201321.","journal-title":"J Infect Dis"},{"key":"761_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2023.105968","volume":"175","author":"B Pinchera","year":"2023","unstructured":"Pinchera B, Moriello NS, Buonomo AR, Zappulo E, Viceconte G, Villari R, et al. Microbiota and hepatitis C virus in the era of direct-acting antiviral agents. Microb Pathog. 2023;175:105968.","journal-title":"Microb Pathog"},{"key":"761_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/srep34055","author":"Y Chen","year":"2016","unstructured":"Chen Y, Ji F, Guo J, Shi D, Fang D, Li L. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Sci Rep. 2016. https:\/\/doi.org\/10.1038\/srep34055.","journal-title":"Sci Rep"},{"issue":"37","key":"761_CR59","first-page":"8379","volume":"22","author":"I Ahmed","year":"2016","unstructured":"Ahmed I, Roy BC, Khan SA, Septer S, Umar S. Microbiome, metabolome and inflammatory bowel disease: systems biology for discovery and translation. World J Gastroenterol. 2016;22(37):8379\u2013401.","journal-title":"World J Gastroenterol"},{"key":"761_CR60","first-page":"1","volume":"11","author":"Q Liu","year":"2019","unstructured":"Liu Q, Li F, Zhuang Y, Xu J, Wang J, Mao X, et al. Liu XJGp: Alter gut microbiota associated with hepat B non-hepat virus related hepatocell carcinoma. 2019;11:1\u201313.","journal-title":"Liu XJGp: Alter gut microbiota associated with hepat B non-hepat virus related hepatocell carcinoma"},{"issue":"7783","key":"761_CR61","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","volume":"575","author":"Y Duan","year":"2019","unstructured":"Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019;575(7783):505\u201311.","journal-title":"Nature"},{"issue":"5","key":"761_CR62","doi-asserted-by":"publisher","first-page":"G824","DOI":"10.1152\/ajpgi.00230.2018","volume":"315","author":"JS Bajaj","year":"2018","unstructured":"Bajaj JS, Matin P, White MB, Fagan A, Deeb JG, Acharya C, et al. Periodontal therapy favorably modulates the oral-gut-hepatic axis in cirrhosis. American J Physiology-Gastrointestinal Liver Physiology. 2018;315(5):G824\u201337.","journal-title":"American J Physiology-Gastrointestinal Liver Physiology"},{"key":"761_CR63","doi-asserted-by":"crossref","unstructured":"Wang X, Zhang B, Jiang R: Microbiome interplays in the gut-liver axis: implications for liver cancer pathogenesis and therapeutic insights. 2025, Volume 15 - 2025.","DOI":"10.3389\/fcimb.2025.1467197"},{"issue":"1","key":"761_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-34765-w","volume":"13","author":"W Zhang","year":"2023","unstructured":"Zhang W, Xu X, Cai L, Cai X. Dysbiosis of the gut microbiome in elderly patients with hepatocellular carcinoma. Sci Rep. 2023;13(1):7797.","journal-title":"Sci Rep"},{"issue":"1","key":"761_CR65","first-page":"2201159","volume":"15","author":"J Yang","year":"2023","unstructured":"Yang J, He Q, Lu F, Chen K, Ni Z, Wang H, et al. A distinct microbiota signature precedes the clinical diagnosis hepatocellular carcinoma. 2023;15(1):2201159.","journal-title":"A distinct microbiota signature precedes the clinical diagnosis hepatocellular carcinoma"},{"issue":"5","key":"761_CR66","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.transproceed.2020.02.049","volume":"52","author":"M Grat","year":"2020","unstructured":"Grat M, Wronka KM, Krasnodebski M, Masior L, Lewandowski Z, Kosinska I, et al. Profile of Gut Microbiota Associated With the Presence of Hepatocellular Cancer in Patients With Liver Cirrhosis. Transpl Proc. 2020;52(5):1556\u201363.","journal-title":"Transpl Proc"},{"issue":"8","key":"761_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081797","volume":"12","author":"E Scarpellini","year":"2024","unstructured":"Scarpellini E, Scarlata GGM, Santori V, Scarcella M, Kobyliak N, Abenavoli L. Gut microbiota, deranged immunity, and hepatocellular carcinoma. Biomedicines. 2024;12(8):1797.","journal-title":"Biomedicines"},{"issue":"1","key":"761_CR68","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1038\/s41598-020-63475-w","volume":"10","author":"L Calder\u00f3n-P\u00e9rez","year":"2020","unstructured":"Calder\u00f3n-P\u00e9rez L, Gosalbes MJ, Yuste S, Valls RM, Pedret A, Llaurad\u00f3 E, et al. Gut metagenomic and short chain fatty acids signature in hypertension: a cross-sectional study. Sci Rep. 2020;10(1):6436.","journal-title":"Sci Rep"},{"issue":"12","key":"761_CR69","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1002\/1873-3468.13064","volume":"592","author":"PB Hylemon","year":"2018","unstructured":"Hylemon PB, Harris SC, Ridlon JM. Metabolism of hydrogen gases and bile acids in the gut microbiome. FEBS Lett. 2018;592(12):2070\u201382.","journal-title":"FEBS Lett"},{"issue":"8","key":"761_CR70","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/ijc.30219","volume":"139","author":"G Xie","year":"2016","unstructured":"Xie G, Wang X, Huang F, Zhao A, Chen W, Yan J, et al. Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int J Cancer. 2016;139(8):1764\u201375.","journal-title":"Int J Cancer"},{"issue":"1","key":"761_CR71","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41420-025-02413-z","volume":"11","author":"Y Wang","year":"2025","unstructured":"Wang Y, Li Y, Lin Y, Cao C, Chen D, Huang X, et al. Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota. Cell Death Discov. 2025;11(1):140.","journal-title":"Cell Death Discov"},{"issue":"1","key":"761_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-017-0683-9","volume":"17","author":"AN Sarangi","year":"2017","unstructured":"Sarangi AN, Goel A, Singh A, Sasi A, Aggarwal R. Faecal bacterial microbiota in patients with cirrhosis and the effect of lactulose administration. BMC Gastroenterol. 2017;17(1):125.","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"761_CR73","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1053\/j.gastro.2019.01.033","volume":"156","author":"JS Bajaj","year":"2019","unstructured":"Bajaj JS, Fagan A, Gavis EA, Kassam Z, Sikaroodi M, Gillevet PM. Long-term outcomes after fecal microbiota transplant in cirrhosis. Gastroenterology. 2019;156(6):1921.","journal-title":"Gastroenterology"},{"issue":"5","key":"761_CR74","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cmet.2020.06.005","volume":"32","author":"TG Oh","year":"2020","unstructured":"Oh TG, Kim SM, Caussy C, Fu T, Guo J, Bassirian S, et al. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab. 2020;32(5):878\u201388.","journal-title":"Cell Metab"},{"issue":"19","key":"761_CR75","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94416","volume":"2","author":"C Acharya","year":"2017","unstructured":"Acharya C, Sahingur SE, Bajaj JS. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight. 2017;2(19):e94416.","journal-title":"JCI Insight"},{"issue":"1","key":"761_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43556-025-00248-9","volume":"6","author":"S Zhang","year":"2025","unstructured":"Zhang S, Huang J, Jiang Z, Tong H, Ma X, Liu Y. Tumor microbiome: roles in tumor initiation, progression, and therapy. Mol Biomed. 2025;6(1):1\u201343.","journal-title":"Mol Biomed"},{"issue":"1","key":"761_CR77","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1186\/s12885-024-12885-4","volume":"24","author":"BD Gamage","year":"2024","unstructured":"Gamage BD, Ranasinghe D, Sahankumari AGP, Malavige GN. Metagenomic analysis of colonic tissue and stool microbiome in patients with colorectal cancer in a South Asian population. BMC Cancer. 2024;24(1):1124.","journal-title":"BMC Cancer"},{"issue":"4","key":"761_CR78","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1002\/hep.28696","volume":"64","author":"DJ Kang","year":"2016","unstructured":"Kang DJ, Betrapally NS, Ghosh SA, Sartor RB, Hylemon PB, Gillevet PM, et al. Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice. Hepatology. 2016;64(4):1232\u201348.","journal-title":"Hepatology"},{"key":"761_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/biology10010055","author":"M El-Mowafy","year":"2021","unstructured":"El-Mowafy M, Elgaml A, El-Mesery M, Sultan S, Ahmed TAE, Gomaa AI, et al. Changes of gut-microbiota-liver axis in hepatitis C virus infection. Biology (Basel). 2021. https:\/\/doi.org\/10.3390\/biology10010055.","journal-title":"Biology (Basel)"},{"issue":"1","key":"761_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s43066-021-00147-y","volume":"11","author":"K Mohieldeen","year":"2021","unstructured":"Mohieldeen K, Hamoda SAF, Ahmed SM, Najeeb A, Ellakany WI. Gut microbiome in cirrhotic hepatitis C virus patients with and without hepatocellular carcinoma. Egypt Liver J. 2021;11(1):79.","journal-title":"Egypt Liver J"},{"issue":"1","key":"761_CR81","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40168-020-00811-2","volume":"8","author":"Y Heshiki","year":"2020","unstructured":"Heshiki Y, Vazquez-Uribe R, Li J, Ni Y, Quainoo S, Imamovic L, et al. Predictable modulation of cancer treatment outcomes by the gut microbiota. Microbiome. 2020;8(1):28.","journal-title":"Microbiome"},{"key":"761_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8111715","author":"S Stojanov","year":"2020","unstructured":"Stojanov S, Berlec A, \u0160trukelj B. The influence of probiotics on the Firmicutes\/Bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease. Microorganisms. 2020. https:\/\/doi.org\/10.3390\/microorganisms8111715.","journal-title":"Microorganisms"},{"key":"761_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2022.111836","volume":"103\u2013104","author":"GR Romualdo","year":"2022","unstructured":"Romualdo GR, Valente LC, Sprocatti AC, Bacil GP, de Souza IP, Rodrigues J, et al. Western diet\u2013induced mouse model of non-alcoholic fatty liver disease associated with metabolic outcomes: Features of gut microbiome-liver-adipose tissue axis. Nutrition. 2022;103\u2013104:111836.","journal-title":"Nutrition"},{"issue":"2","key":"761_CR84","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2240031","volume":"15","author":"J Rajapakse","year":"2023","unstructured":"Rajapakse J, Khatiwada S, Akon AC, Yu KL, Shen S, Zekry A. Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions. Gut Microbes. 2023;15(2):2240031.","journal-title":"Gut Microbes"},{"issue":"1","key":"761_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02075-w","volume":"10","author":"J Zheng","year":"2025","unstructured":"Zheng J, Wang S, Xia L, Sun Z, Chan KM, Bernards R, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Ther. 2025;10(1):35.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"761_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062578","volume":"8","author":"L Krych","year":"2013","unstructured":"Krych L, Hansen CH, Hansen AK, van den Berg FW, Nielsen DS. Quantitatively different, yet qualitatively alike: a meta-analysis of the mouse core gut microbiome with a view towards the human gut microbiome. PLoS ONE. 2013;8(5):e62578.","journal-title":"PLoS ONE"},{"key":"761_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.905653","volume":"12","author":"F Nie","year":"2022","unstructured":"Nie F, Wang L, Huang Y, Yang P, Gong P, Feng Q, et al. Characteristics of microbial distribution in different oral niches of oral squamous cell carcinoma. Front Cell Infect Microbiol. 2022;12:905653.","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"761_CR88","volume":"34","author":"I P\u00e9rez-Prieto","year":"2024","unstructured":"P\u00e9rez-Prieto I, Migueles Jairo H, Molina Nerea M, Sola-Leyva A, Salas-Espejo E, Arffman Riikka K, et al. Association Accelerometer-Determined Physical Activity Sedentary Behavior With the Gut Microbiome in Middle-Aged Women: A Compositional Data Approach. 2024;34(7):e14689.","journal-title":"Association Accelerometer-Determined Physical Activity Sedentary Behavior With the Gut Microbiome in Middle-Aged Women: A Compositional Data Approach"},{"issue":"1","key":"761_CR89","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.hbpd.2018.11.002","volume":"18","author":"J-W Jiang","year":"2019","unstructured":"Jiang J-W, Chen X-H, Ren Z, Zheng S-S. Gut microbial dysbiosis associates hepatocellular carcinoma through the gut-liver axis. Hepatobiliary Pancreat Dis Int. 2019;18(1):19\u201327.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"5","key":"761_CR90","doi-asserted-by":"publisher","first-page":"e00245","DOI":"10.1128\/mbio.00245-24","volume":"15","author":"Y Guo","year":"2024","unstructured":"Guo Y, Tian S, Zhan N, Liu C, Li J, Hu J, et al. Ascitic microbiota alteration is associated with portal vein tumor thrombosis occurrence and prognosis in hepatocellular carcinoma. MBio. 2024;15(5):e00245-e1224.","journal-title":"MBio"},{"key":"761_CR91","doi-asserted-by":"crossref","unstructured":"Chen L, Wang W, Zhou R, Ng SC, Li J, Huang M, Zhou F, Wang X, Shen B, M AK et al: Characteristics of fecal and mucosa-associated microbiota in Chinese patients with inflammatory bowel disease. Medicine 2014, 93(8):e51.","DOI":"10.1097\/MD.0000000000000051"},{"issue":"6","key":"761_CR92","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004779","volume":"10","author":"P-C Lee","year":"2022","unstructured":"Lee P-C, Wu C-J, Hung Y-W, Lee CJ, Chi C-T, Lee IC, et al. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor\u2013treated unresectable hepatocellular carcinoma. J Immunother Cancer. 2022;10(6):e004779.","journal-title":"J Immunother Cancer"},{"issue":"7516","key":"761_CR93","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature13568","volume":"513","author":"N Qin","year":"2014","unstructured":"Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513(7516):59\u201364.","journal-title":"Nature"},{"issue":"1","key":"761_CR94","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2473504","volume":"17","author":"J Yao","year":"2025","unstructured":"Yao J, Beifang N, Ding J. The gut microbiota: an emerging modulator of drug resistance in hepatocellular carcinoma. Gut Microbes. 2025;17(1):2473504.","journal-title":"Gut Microbes"},{"issue":"7","key":"761_CR95","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.trecan.2022.02.009","volume":"8","author":"MAD Silveira","year":"2022","unstructured":"Silveira MAD, Bilodeau S, Greten TF, Wang XW, Trinchieri G. The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis. Trends Cancer. 2022;8(7):583\u201397.","journal-title":"Trends Cancer"},{"key":"761_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60071150","author":"T Matsui","year":"2024","unstructured":"Matsui T, Morozumi T, Yamamoto Y, Kobayashi T, Takuma R, Yoneda M, et al. Relationship of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma with oral and intestinal microbiota: a cross-sectional pilot study. Medicina (B Aires). 2024. https:\/\/doi.org\/10.3390\/medicina60071150.","journal-title":"Medicina (B Aires)"},{"key":"761_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2020.104479","volume":"149","author":"D Li","year":"2020","unstructured":"Li D, Xi W, Zhang Z, Ren L, Deng C, Chen J, et al. Oral microbial community analysis of the patients in the progression of liver cancer. Microb Pathog. 2020;149:104479.","journal-title":"Microb Pathog"},{"issue":"8","key":"761_CR98","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1136\/gutjnl-2013-304833","volume":"63","author":"K Machiels","year":"2014","unstructured":"Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63(8):1275\u201383.","journal-title":"Gut"},{"key":"761_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.fbio.2024.103852","volume":"59","author":"R Pan","year":"2024","unstructured":"Pan R, Chen Y, Lin G, Wang H, Xu X, Wang L, et al. Imbalances in the gut microbiota and metabolome are associated with functional constipation in pregnancy. Food Biosci. 2024;59:103852.","journal-title":"Food Biosci"},{"issue":"12","key":"761_CR100","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1681\/ASN.2022020189","volume":"33","author":"J Zhao","year":"2022","unstructured":"Zhao J, Bai M, Ning X, Qin Y, Wang Y, Yu Z, et al. Expansion of Escherichia-Shigella in gut is associated with the onset and response to immunosuppressive therapy of IgA nephropathy. J Am Soc Nephrol. 2022;33(12):2276\u201392.","journal-title":"J Am Soc Nephrol"},{"key":"761_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12866-020-02074-1","volume":"21","author":"Y Xie","year":"2021","unstructured":"Xie Y, Sun J, Wei L, Jiang H, Hu C, Yang J, et al. Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals. BMC Microbiol. 2021;21:1\u201312.","journal-title":"BMC Microbiol"},{"issue":"10","key":"761_CR102","doi-asserted-by":"publisher","first-page":"873","DOI":"10.21037\/atm-21-2158","volume":"9","author":"T Zhang","year":"2021","unstructured":"Zhang T, Li J, Liu C-P, Guo M, Gao C-L, Zhou L-P, et al. Butyrate ameliorates alcoholic fatty liver disease through reducing endotoxemia and inhibiting liver gasdermin D-mediated pyroptosis. Ann Transl Med. 2021;9(10):873.","journal-title":"Ann Transl Med"},{"issue":"9","key":"761_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/nu12092762","volume":"12","author":"D Ferro","year":"2020","unstructured":"Ferro D, Baratta F, Pastori D, Cocomello N, Colantoni A, Angelico F, et al. New insights into the pathogenesis of non-alcoholic fatty liver disease: gut-derived lipopolysaccharides and oxidative stress. Nutrients. 2020;12(9):2762.","journal-title":"Nutrients"},{"issue":"3","key":"761_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030524","volume":"10","author":"Q Song","year":"2022","unstructured":"Song Q, Zhang X. The role of gut\u2013liver axis in gut microbiome dysbiosis associated NAFLD and NAFLD-HCC. Biomedicines. 2022;10(3):524.","journal-title":"Biomedicines"},{"key":"761_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8111724","author":"N Souai","year":"2020","unstructured":"Souai N, Zidi O, Mosbah A, Kosai I, Manaa JE, Mokhtar NB, et al. Impact of the post-transplant period and lifestyle diseases on human gut microbiota in kidney graft recipients. Microorganisms. 2020. https:\/\/doi.org\/10.3390\/microorganisms8111724.","journal-title":"Microorganisms"},{"issue":"5","key":"761_CR106","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1021\/acsinfecdis.0c00432","volume":"7","author":"S Sultan","year":"2021","unstructured":"Sultan S, El-Mowafy M, Elgaml A, El-Mesery M, El Shabrawi A, Elegezy M, et al. Alterations of the treatment-naive gut microbiome in newly diagnosed Hepatitis C virus infection. ACS Infect Dis. 2021;7(5):1059\u201368.","journal-title":"ACS Infect Dis"},{"issue":"22","key":"761_CR107","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1158\/0008-5472.CAN-23-0401","volume":"83","author":"D Zhou","year":"2023","unstructured":"Zhou D, Zhang M, Li R. Bacterial \u03b2-glucuronidase reactivates estrogen-DNA adducts in hepatocellular carcinoma. Cancer Res. 2023;83(22):3788\u201399.","journal-title":"Cancer Res"},{"issue":"4","key":"761_CR108","volume":"13","author":"M Nakashima","year":"2025","unstructured":"Nakashima M, Fukumoto A, Matsuda S. Beneficial probiotics with new cancer therapies for improved treatment of hepatocellular carcinoma. Dis Markers. 2025;13(4):111.","journal-title":"Dis Markers"},{"key":"761_CR109","doi-asserted-by":"crossref","unstructured":"Yuan H, Zhou J, Wu X, Wang S, Park S 2025: Enterotype-stratified gut microbial signatures in MASLD and cirrhosis based on integrated microbiome data. Frontiers in Microbiology, Volume 16 2025.","DOI":"10.3389\/fmicb.2025.1568672"},{"key":"761_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115225","volume":"204","author":"D Beyo\u011flu","year":"2022","unstructured":"Beyo\u011flu D, Idle JR. The gut microbiota\u2013a vehicle for the prevention and treatment of hepatocellular carcinoma. Biochem Pharmacol. 2022;204:115225.","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"761_CR111","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","volume":"20","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Willoughby CE, Singal AG, Greten TF, Heikenw\u00e4lder M, El-Serag HB, et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat Rev Gastroenterol Hepatol. 2023;20(8):487\u2013503.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"761_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7528","volume":"6","author":"Q Feng","year":"2015","unstructured":"Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun. 2015;6:6528.","journal-title":"Nat Commun"},{"issue":"11","key":"761_CR113","doi-asserted-by":"publisher","first-page":"6103","DOI":"10.1039\/D1FO04178A","volume":"13","author":"HH Shi","year":"2022","unstructured":"Shi HH, Chen LP, Wang CC, Zhao YC, Wang YM, Xue CH, et al. Docosahexaenoic acid-acylated curcumin diester alleviates cisplatin-induced acute kidney injury by regulating the effect of gut microbiota on the lipopolysaccharide- and trimethylamine-N-oxide-mediated PI3K\/Akt\/NF-\u03baB signaling pathway in mice. Food Funct. 2022;13(11):6103\u201317.","journal-title":"Food Funct"},{"issue":"1","key":"761_CR114","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-024-05532-5","volume":"81","author":"XJ Li","year":"2024","unstructured":"Li XJ, Shan QY, Wu X, Miao H, Zhao YY. Gut microbiota regulates oxidative stress and inflammation: a double-edged sword in renal fibrosis. Cell Mol Life Sci. 2024;81(1):480.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"761_CR115","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41423-020-00592-6","volume":"18","author":"R Wang","year":"2021","unstructured":"Wang R, Tang R, Li B, Ma X, Schnabl B. Gut microbiome, liver immunology, and liver diseases. Cell Mol Immunol. 2021;18(1):4\u201317.","journal-title":"Cell Mol Immunol"},{"key":"761_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100998","volume":"57","author":"F Violi","year":"2023","unstructured":"Violi F, Pignatelli P, Castellani V, Carnevale R, Cammisotto V. Gut dysbiosis, endotoxemia and clotting activation: a dangerous trio for portal vein thrombosis in cirrhosis. Blood Rev. 2023;57:100998.","journal-title":"Blood Rev"},{"issue":"5","key":"761_CR117","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/gutjnl-2020-320930","volume":"70","author":"J-Y Shi","year":"2021","unstructured":"Shi J-Y, Wang X, Ding G-Y, Dong Z, Han J, Guan Z, et al. Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning. Gut. 2021;70(5):951.","journal-title":"Gut"},{"key":"761_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2024.106726","volume":"193","author":"RP Shastry","year":"2024","unstructured":"Shastry RP, Ghate SD, Hameed A, Rao RSP, Bhandary YP, Shetty R. Emergence of rare and low abundant anaerobic gut Firmicutes is associated with a significant downfall of Klebsiella in human colon cancer. Microb Pathog. 2024;193:106726.","journal-title":"Microb Pathog"},{"issue":"4","key":"761_CR119","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/S1556-0864(18)30365-4","volume":"13","author":"L Zhang","year":"2018","unstructured":"Zhang L, Chen J. 90P study of intestinal flora differences between small cell lung cancer (SCLC) patients and healthy people. J Thorac Oncol. 2018;13(4):S49\u201350.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"761_CR120","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27\u201341.","journal-title":"Immunity"},{"issue":"1","key":"761_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-020-1793-3","volume":"18","author":"H Lee","year":"2020","unstructured":"Lee H, Lee HK, Min SK, Lee WH. 16S rDNA microbiome composition pattern analysis as a diagnostic biomarker for biliary tract cancer. World J Surg Oncol. 2020;18(1):19.","journal-title":"World J Surg Oncol"},{"key":"761_CR122","doi-asserted-by":"crossref","unstructured":"Yu AI, Zhao L, Eaton KA, Ho S, Chen J, Poe S, Becker J, Gonzalez A, McKinstry D, Hasso M: Gut Microbiota Modulate CD8 T Cell Responses to Influence Colitis-Associated Tumorigenesis., 2020, 31. https:\/\/doi.org\/101016\/j celrep 2020 2020, 35:107471.","DOI":"10.1016\/j.celrep.2020.03.035"},{"key":"761_CR123","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejca.2021.03.053","volume":"151","author":"G Zhu","year":"2021","unstructured":"Zhu G, Su H, Johnson CH, Khan SA, Kluger H, Lu LJ. Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma. Eur J Cancer. 2021;151:25\u201334.","journal-title":"Eur J Cancer"},{"issue":"3","key":"761_CR124","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s12094-021-02725-3","volume":"24","author":"AW Mao","year":"2022","unstructured":"Mao AW, Barck H, Young J, Paley A, Mao JH, Chang H. Identification of a novel cancer microbiome signature for predicting prognosis of human breast cancer patients. Clin Transl Oncol. 2022;24(3):597\u2013604.","journal-title":"Clin Transl Oncol"},{"issue":"7","key":"761_CR125","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1136\/gutjnl-2019-318532","volume":"69","author":"JQ Liang","year":"2020","unstructured":"Liang JQ, Li T, Nakatsu G, Chen Y-X, Yau TO, Chu E, et al. A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer. Gut. 2020;69(7):1248\u201357.","journal-title":"Gut"},{"issue":"1","key":"761_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010210","volume":"15","author":"M-W Lai","year":"2022","unstructured":"Lai M-W, Chu Y-D, Hsu C-W, Chen Y-C, Liang K-H, Yeh C-TJC. Multi-omics analyses identify signatures in patients with liver cirrhosis and hepatocellular carcinoma. Cancers. 2022;15(1):210.","journal-title":"Cancers"},{"issue":"4","key":"761_CR127","doi-asserted-by":"publisher","first-page":"159","DOI":"10.12938\/bmfh.18-029","volume":"38","author":"R Shinohara","year":"2019","unstructured":"Shinohara R, Sasaki K, Inoue J, Hoshi N, Fukuda I, Sasaki D, et al. Butyryl-CoA:acetate CoA-transferase gene associated with the genus Roseburia is decreased in the gut microbiota of Japanese patients with ulcerative colitis. Biosci Microbiota Food Health. 2019;38(4):159\u201363.","journal-title":"Biosci Microbiota Food Health"},{"issue":"5","key":"761_CR128","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3390\/molecules29050976","volume":"29","author":"H Xu","year":"2024","unstructured":"Xu H, Yuan M, Niu K, Yang W, Jiang M, Zhang L, et al. Involvement of bile acid metabolism and gut microbiota in the amelioration of experimental metabolism-associated fatty liver disease by nobiletin. Molecules. 2024;29(5):976.","journal-title":"Molecules"},{"key":"761_CR129","doi-asserted-by":"crossref","unstructured":"Wise JL, Cummings BP: The 7-\u03b1-dehydroxylation pathway: An integral component of gut bacterial bile acid metabolism and potential therapeutic target. Frontiers in Microbiology 2023, Volume 13 - 2022.","DOI":"10.3389\/fmicb.2022.1093420"},{"key":"761_CR130","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.631552","volume":"9","author":"Y Sui","year":"2021","unstructured":"Sui Y, Wu J, Chen J. The role of gut microbial \u03b2-glucuronidase in estrogen reactivation and breast cancer. Front Cell Dev Biol. 2021;9:631552.","journal-title":"Front Cell Dev Biol"},{"key":"761_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.1104399","volume":"12","author":"K Shi","year":"2022","unstructured":"Shi K, Zhang Q, Zhang Y, Bi Y, Zeng X, Wang X. Association between probiotic therapy and the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis. Front Cell Infect Microbiol. 2022;12:1104399.","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"761_CR132","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jhep.2021.09.010","volume":"76","author":"VC Patel","year":"2022","unstructured":"Patel VC, Lee S, McPhail MJW, Da Silva K, Guilly S, Zamalloa A, et al. Rifaximin-\u03b1 reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. J Hepatol. 2022;76(2):332\u201342.","journal-title":"J Hepatol"},{"issue":"1","key":"761_CR133","doi-asserted-by":"publisher","first-page":"14413","DOI":"10.1038\/s41598-023-41664-7","volume":"13","author":"N Chuaypen","year":"2023","unstructured":"Chuaypen N, Jinato T, Avihingsanon A, Nookaew I, Tanaka Y, Tangkijvanich P. Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection. Sci Rep. 2023;13(1):14413.","journal-title":"Sci Rep"},{"issue":"15","key":"761_CR134","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.3390\/nu16152454","volume":"16","author":"F Fogacci","year":"2024","unstructured":"Fogacci F, Giovannini M, Di Micoli V, Grandi E, Borghi C, Cicero AFG. Effect of supplementation of a butyrate-based formula in individuals with liver steatosis and metabolic syndrome: a randomized double-blind placebo-controlled clinical trial. Nutrients. 2024;16(15):2454.","journal-title":"Nutrients"}],"container-title":["Gut Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13099-025-00761-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13099-025-00761-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13099-025-00761-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T19:03:47Z","timestamp":1763147027000},"score":1,"resource":{"primary":{"URL":"https:\/\/gutpathogens.biomedcentral.com\/articles\/10.1186\/s13099-025-00761-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":134,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1186\/s13099-025-00761-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7130645\/v1","asserted-by":"object"}]},"ISSN":["1757-4749"],"issn-type":[{"value":"1757-4749","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of the Faculty of Pharmacy, Suez Canal University (Approval No. 2023\/0NH1). All participants provided written informed consent in accordance with the ethical principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"88"}}